DMRA · XBRL financial data

Damora Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DMRA's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Research and development	2,768*	2,463	1,834	1,093	1,008*	678	1,465	1,416	23,318*	23,777	25,540	25,475
General and administrative	3,183*	3,278	2,775	2,747	1,699*	1,921	1,956	1,740	4,068*	7,034	9,454	11,388
Total operating expenses	6,671*	5,741	5,577	3,840	7,102*	2,599	3,421	3,156	201,696*	30,811	34,994	36,863
Operating income (loss)	(6,671)*	(5,741)	(5,577)	(3,840)	(7,102)*	(2,599)	(3,421)	(3,156)	(201,696)*	(30,811)	(34,994)	(36,863)
Income tax expense (benefit)	year only	—	42	7	(8)*	2	4	0	44*	42	255	0
Net income (loss)	(6,475)*	(5,477)	(5,338)	(3,883)	(6,741)*	(2,533)	(3,437)	(3,133)	(200,736)*	(27,783)	(31,174)	(31,991)
Earnings per share, basic‡ USD per share	(6.00)*	(5.00)	(5.00)	(3.39)	(5.13)*	(1.92)	(2.60)	(2.36)	—	(0.62)	(0.39)	(0.40)
Earnings per share, diluted‡ USD per share	(6.00)*	(5.00)	(5.00)	(3.39)	(5.13)*	(1.92)	(2.60)	(2.36)	—	(0.62)	(0.39)	(0.40)
Weighted average shares, basic‡ thousands of shares	1,085*	1,085	1,085	1,145	1,313*	1,322	1,323	1,327	1,479*	34,299	61,117	61,810
Weighted average shares, diluted‡ thousands of shares	1,085*	1,085	1,085	1,145	1,313*	1,322	1,323	1,327	1,479*	34,299	61,117	61,810

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.
† Share count changed about 45x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (DMRA's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	21,465	21,091	22,862	19,678	14,175	11,939	10,211	7,606	257,624	532,899	540,515	349,656
Marketable securities	11,686	6,080	—	—	—	—	—	—	0	—	—	178,822
Prepaid and other current assets	3,623	3,370	2,306	1,500	2,664	2,984	2,816	2,180	2,799	2,509	3,073	2,839
Total current assets	36,774	30,541	25,168	21,178	16,839	14,923	13,027	9,786	260,423	535,408	543,588	531,317
Property and equipment, net	78	73	67	62	57	52	47	41	36	—	—	—
Right-of-use asset	247	152	76	32	73	73	75	72	68	—	—	830
Total assets	38,227	32,477	27,297	23,376	17,132	15,365	13,691	10,736	260,527	535,442	543,636	532,627
Accounts payable	1,702	1,665	724	503	377	354	756	520	444	819	3,482	6,084
Accrued liabilities	4,128	2,653	2,985	1,938	820	1,197	1,873	2,103	2,401	5,997	8,879	12,830
Total current liabilities	5,830	4,318	3,709	2,441	1,197	1,551	2,629	2,623	20,066	23,812	27,550	35,892
Lease liability, non-current	66	—	—	—	61	60	60	57	53	—	—	946
Total liabilities	5,896	4,318	3,709	2,441	1,301	1,656	2,738	2,729	20,147	23,839	27,577	36,866
Accumulated deficit	(256,085)	(261,562)	(266,900)	(270,783)	(277,524)	(280,057)	(283,494)	(286,627)	(487,363)	(515,146)	(546,320)	(578,311)
Total stockholders' equity	32,331	28,159	23,588	20,935	15,831	13,709	10,953	8,007	240,380	511,603	516,059	495,761
Total liabilities and equity	38,227	32,477	27,297	23,376	17,132	15,365	13,691	10,736	260,527	535,442	543,636	532,627
Common shares outstanding (cover page)‡ thousands of shares	1,085	1,085	1,085	1,317	1,322	1,322	1,325	1,327	60,303	61,553	61,736	61,905

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.
† Share count changed about 45x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (DMRA's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(6,475)*	(5,477)	(5,338)	(3,883)	(6,741)*	(2,533)	(3,437)	(3,133)	(200,736)*	(27,783)	(31,174)	(31,991)
Stock-based compensation	1,090*	1,359	891*	681*	308*	179	172*	164*	483*	3,134	6,144*	7,541*
Net cash from operating activities	(11,474)*	(5,936)	(4,100)*	(3,651)*	(4,936)*	(2,439)	(2,237)*	(2,616)*	566*	(20,598)	(21,867)*	(17,234)*
Net cash from investing activities	9,580*	5,650	6,000*	0*	0*	—	—	—	year only	—	—	—
Proceeds from issuing common stock	0*	—	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	0*	—	—	—	—	—	—	—	year only	295,921	29,505*	5,119*

† Share count changed about 45x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Damora Therapeutics	349,656	not reported	(17,234)*	61.9M	26.6 quarters	Q3 FY26 10-QSep 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.